NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Latus Bio

Latus Bio

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://www.latusbio.com/

Last Round

Series A

May 4, 2026

Total Funding Raised

$194M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Latus Bio is a biotechnology company that develops precision gene therapies for central nervous system and peripheral diseases using proprietary AAV capsid engineering and computational discovery platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

gene therapycapsid engineeringAAVCNS disordersadeno-associated virusneurological diseasecentral nervous systemdrug discoveryprecision medicinetherapeutic deliverybiotechAI drug discoverytissue-specific transductiongenerative biologyin-vivo screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Latus Bio Comps

Public and private peers based on sector, stage, and business model.

Latus Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Latus Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 4, 2026
Series AMay 2, 2024

Key People

Founding team and executive leadership

John Tattory

Consulting CFO

Executive Team

Ainslie Little

Chief Operating Officer

Executive Team

Latus Bio Investors

Notable investors and investment history

Latus Bio investors
InvestorRounds
Helen's Pink Sky FoundationSeries A
Benjamin Franklin Technology PartnersSeries A
DCVC BioSeries A
GaingelsSeries A
Korea Development BankSeries A
BioAdvance CapitalSeries A
8VCSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2026

    $97M round led by 8VC and DCVC Bio.

  • Nov 3, 2025

    Launched an AI/ML strategy for AAV gene therapy and added two scientific advisors.

Latus Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Latus Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Latus Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range27
Year Founded2024
Last FundingMay 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.